Results 141 to 150 of about 1,831,254 (293)

A Kinetic Approach To The Definition Of Pathophysiology Of Low Antithrombin III (AT) Levels In Patients [PDF]

, 1981
E. B. Reeve, B. D. Leonard, R. D. Bies, Daniel R. Ambruso, William E. Hathaway   +4 more
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Combined Hill-Sachs remplissage and Latarjet procedure: does glenoid track help decision making?

JSES International
Background: We aim to analyze recurrence of dislocation after Latarjet bone block with or without Hill-Sachs Remplissage (HSR) to specify the indication of a combined procedure.
Bastien Bige, MD, Nicolas Recanatesi, MD, Jean Francois Gonzalez, MD, Marc-Olivier Gauci, MD, PhD   +3 more
doaj  

Changes in digestive enzyme levels in carp after feeding. III. Response of protease and amylase to twice-a-day feeding.

, 1976
Toshio Onishi, Shigeo Murayama, Masaaki Takeuchi   +2 more
openalex   +2 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The challenges in establishing and Upholding an adult Level III epilepsy center in an underserved area in the United states. [PDF]

Epilepsy Behav Rep
Dao KT, Chacko C, Braich S, Liu L, Zalmay N, Nguyen C, Radhakrishnan K, Liu CY, Kunhi-Veedu HP.   +8 more
europepmc   +1 more source

Update of antimicrobial resistance in level III and IV health institutions in Colombia between January 2018 and December 2021 [PDF]

Biomedica, 2023
De La Cadena E, Pallares CJ, García-Betancur JC, Porras JA, Villegas MV.   +4 more
europepmc   +1 more source

Geologic and hydrologic characterization and evaluation of the Basin and Range Province relative to the disposal of high-level radioactive waste: Part III, Geologic and hydrologic evaluation [PDF]

, 1983
M.S. Bedinger, Kenneth A. Sargent, Bruce T. Brady   +2 more
openalex   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Antimicrobial Consumption and Resistance of Restricted Antibiotics in a Level III Government Hospital. [PDF]

Acta Med Philipp
Abeleda MA, Peña I, Salenga R, Capule F, Nacabu-An SM, Nala P.   +5 more
europepmc   +1 more source